GI Biome, a subsidiary of GI Innovation, is changing its name to 'GI Longevity' and is set to target the global anti-aging market.
GI Biome noted on the 11th that the name change proposal was approved at the shareholders' meeting held on the 8th.
GI Longevity is anticipating the potential for developing anti-aging treatments, having confirmed the effects of 'GIB-7', developed using microbiome technology, in preclinical studies such as muscle strengthening and improving sleep quality in the elderly.
GI Innovation and GI Longevity are preparing clinical trials for the immuno-oncological drug 'GI-102' and the microbiome combination drug 'GIB-7' targeting the elderly in Australia and Korea. The company is also developing additional pipelines to enhance immune, cognitive, and muscle functions and plans to accelerate its goal of extending 'healthy lifespan' by maximizing synergies with technologies from its subsidiary, such as the self-derived natural killer (NK) cell therapy.
Yang Bo-gi, CEO of GI Longevity, said, "This name change is a milestone declaring a new identity and direction externally," adding, "We will leverage our entry into the finals of next year's XPRIZE to lead the global anti-aging industry."